No Data
No Data
Humacyte's HAV: A Game-Changer for Underserved Hemodialysis Patients
Humacyte Price Target Maintained With a $4.00/Share by Piper Sandler
Humacyte Price Target Maintained With a $4.00/Share by Piper Sandler
Express News | Piper Sandler Maintains Neutral on Humacyte, Maintains $4 Price Target
Piper Sandler Sticks to Its Hold Rating for Humacyte (HUMA)
Humacyte to Host Virtual KOL Event "Hemodialysis Access: A Crossroads of Care," on March 28, 2024
PDF Version DURHAM, N.C., March 26, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered hum
Benchmark Reiterates Buy on Humacyte, Maintains $15 Price Target
Benchmark analyst Bruce Jackson reiterates Humacyte with a Buy and maintains $15 price target.
No Data